Biotechnology Podcast: LSD ‘Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics’ Says MindMed’s R. Barrow – Mind Medicine (NASDAQ:MNMD) Read more
Biotechnology MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds – Mind Medicine (NASDAQ:MNMD) Read more
Biotechnology MindMed Receives FDA ‘Breakthrough Therapy’ Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials – Compass Pathways (NASDAQ:CMPS), Mind Medicine (NASDAQ:MNMD) Read more
Biotechnology MindMed’s 2023 Financial Results And Business Recap: Milestones Amid Rising Expenses – Mind Medicine (NASDAQ:MNMD) Read more
Biotechnology FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000 – Johnson & Johnson (NYSE:JNJ), Mind Medicine (NASDAQ:MNMD) Read more
